Clinical trials: Downstaging
Rectal Cancer
Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer
The purpose of this study is to establish the influence of time-interval between preoperative hyperfractionated radiotherapy (5x5 Gy) and surgery on long term overall survival (5 years), local and distant recurrence rate…
- Trial name
- NCT01444495
- Testing
- Preoperative radiotherapy, Surgery
- Where
- Poland
- Volunteers
- 154 people
- Sponsor
- Jagiellonian University
Perihilar Cholangiocarcinoma, Klatskin Tumor
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cholangiocarcinoma using…
- Trial name
- pCOLA (NCT06986486)
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hepatocellular Carcinoma (HCC), Macrovascular Invasion
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation.
- Conditions
- Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
- Trial name
- MacroTrans (NCT06725121)
- Testing
- Atezolizumab & Bevacizumab, Yttrium-90 (Y-90), Stereotactic body radiotherapy (SBRT)
- Where
- 2 sites in Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Locally Advanced Rectal Carcinoma
Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer
The goal of this clinical trial is to investigate if the addition of modulated electro-hyperthermia (mEHT) improves tumor down-staging and pathological response in adult patients (20 years and above) with locally advanced rectal…
- Trial name
- mEHT (NCT07372300)
- Testing
- Hyperthermia
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Shih-Kai Hung
Adenocarcinoma of the Rectum, Adenocarcinoma
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
The aim of this study is to determine whether greater rectal cancer downstaging and regression occurs when surgery is delayed to 12 weeks after completion of radiotherapy/chemotherapy compared to 6 weeks.
- Conditions
- Adenocarcinoma of the Rectum, Adenocarcinoma, Adenocarcinoma, Mucinous, Carcinoma
- Trial name
- NCT01037049
- Testing
- Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
- Where
- 23 sites in Brazil, Canada and 2 more
- Volunteers
- 237 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Hepatocellular Carcinoma
The ImmunoXXL Study
This study is aimed at confirming data of efficacy and safety of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) beyond current transplant criteria who demonstrate a sustained partial or complete…
- Trial name
- ImmunoXXL (NCT05879328)
- Testing
- Liver Transplantation
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung…
- Conditions
- Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
- Trial name
- DRAGON-NSCLC (NCT07528066)
- Testing
- Robotic-assisted surgery (RATS)
- Where
- 10 sites in China, France and 1 more
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
HCC - Hepatocellular Carcinoma
Downstaging Prediction Model for HCC
This study is a real-world, single-center study that collects imaging and clinical data from patients with HCC who are downstaged beyond the UCSF criteria.
- Trial name
- NCT07058649
- Volunteers
- 369 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma, Liver Transplant
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver transplantation.
- Trial name
- NCT04035876
- Testing
- Camrelizumab plus apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Prostate Cancer (Adenocarcinoma)
Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
The PARIS-BIO study evaluates whether a novel genomic biomarker, the PCAI ImmunoScore, can predict the response to neoadjuvant treatment with Darolutamide in patients with high-risk localized or locally advanced prostate cancer.
- Trial name
- PARIS-BIO (NCT07617272)
- Testing
- Darolutamide, Radical prostatectomy
- Where
- 2 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Region Stockholm
HCC
Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy
This study is a prospective phase II, single arm clinical study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and…
- Trial name
- START-FIT (NCT03817736)
- Testing
- TACE, SBRT, Immune Checkpoint Inhibitor
- Where
- Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma Non-resectable
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or…
- Trial name
- CCGLC-008 (NCT05717738)
- Testing
- TACE, Lenvatinib, Anti-PD-1 monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
HCC - Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide.
- Trial name
- NCT07305428
- Testing
- Stereotactic Body Radiation Therapy followed by Immunotherapy
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Hepato Cellular Carcinoma
IIT2025-03-YANG-LIFT-HCC
The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC).
- Trial name
- NCT07489976
- Testing
- STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Ju Dong Yang
Hepatocellular Carcinoma
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.
- Trial name
- NCT04974281
- Testing
- PD-1 and Lenvatinib Plus TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Cholangiocellular Carcinoma
Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy
An open label, prospective, non-randomized single arm study. Combination of two treatment modalities - HAI with FUDR and systemic chemotherapy with cisplatin and gemcitabine.
- Trial name
- NCT01692704
- Testing
- Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University of Zurich
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue in patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01194206
- Testing
- stereotactic body radiation therapy
- Sponsor
- Case Comprehensive Cancer Center
HCC
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE)…
- Trial name
- NCT04988945
- Testing
- TACE, SBRT, Durvalumab
- Where
- 2 sites in Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Non Small Cell Lung Cancer
Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)
The purpose of this study is to evaluate the safety and efficacy of neoadjuvant targeted therapy followed by surgery in participants with advanced non-small cell lung cancer.
- Trial name
- NCT05085054
- Testing
- Osimertinib Mesylate
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma
Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
This is a multicenter, randomized, parallel controlled study to determine the efficacy and safety of transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma beyond University of California, San…
- Trial name
- NCT04738188
- Testing
- DEB-TACE, cTACE, Drug-eluting Beads
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital